FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry and represents a new IL-6 binding antibody, as well as to methods of treating an IL-6 mediated disorder and improving a condition in an animal suffering the IL-6 mediated cancer disorders with using the above antibody. The invention also refers to a kit containing the antibody, as well as to transgenic plants and animals able to express the above antibody.
EFFECT: invention enables extending the range of high-affinity IL-6 antibodies.
36 cl, 44 dwg, 10 ex
Title | Year | Author | Number |
---|---|---|---|
IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
ANTI-CXCR4 ANTIBODIES FOR TREATMENT OF HIV INFECTION | 2010 |
|
RU2573902C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
Authors
Dates
2014-11-10—Published
2009-11-13—Filed